NCT07210775 2026-03-04
Topical Imiquimod Treatment of Oral Dysplasia
University of Southern California
Phase 1/2 Recruiting
Clinical Trials
7 trialsNCT02078648 2025-02-03
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT03559413 2023-12-04
Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL
University Children's Hospital Tuebingen
Phase 1/2 Completed
NCT01421017 2021-11-18
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases
NYU Langone Health
Phase 1/2 Completed
NCT02224599 2020-04-24
Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies
Kiromic BioPharma Inc.
Phase 1/2 Terminated
NCT02452307 2017-08-17
Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy
University Hospital Tuebingen
Phase 1/2 Unknown
NCT00785122 2013-05-16
IMA910-101
Immatics Biotechnologies GmbH
Phase 1/2 Completed